Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis

Back to Search
Print
Bookmark Trial

NCT02092467

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer BioBank - Biomedical Systems
Groton, Connecticut, 06340, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Arthritis, Rheumatoid
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
50 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Moderate to severe rheumatoid arthritis

- Taking methotrexate without adequate control of symptoms

- Have at least one cardiovascular risk factor (eg, current smoker, high blood pressure, high cholesterol levels, diabetes mellitus, history of heart attack, family history of coronary heart disease, extra-articular RA disease)

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Current or recent infection


- Clinically significant laboratory abnormalities


- Pregnancy

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Arthritis, RheumatoidStudy of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate NCT00628095
  1. Mesa, Arizona
  2. Debary, Florida
  3. Lake Mary, Florida
  4. Tampa, Florida
  5. Avon, Indiana
  6. New Orleans, Louisiana
  7. Frederick, Maryland
  8. Columbia, Missouri
  9. Columbia, Missouri
  10. Reno, Nevada
  11. Cincinnati, Ohio
  12. Spokane, Washington
  13. Providencia, Santiago, RM
  14. Ceska Lipa,
  15. Praha 2,
  16. Praha 4,
  17. Incheon,
  18. Pusan,
  19. Mexico, D.f.
  20. Krakow,
  21. Poznan,
  22. Poznan,
  23. Santiago de Compostela, A Coruña
  24. A Coruña,
  25. Madrid,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Arthritis, RheumatoidEtanercept (Enbrel) Special Investigation (Regulatory Post Marketing Commitment Plan) NCT01230177
  1. Sendai, Miyagi
ALL GENDERS
16 Years+
years
MULTIPLE SITES
Arthritis, RheumatoidStudy of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors NCT00960440
  1. Birmingham, Alabama
  2. Los Angeles, California
  3. Los Angeles, California
  4. San Diego, California
  5. Farmington, Connecticut
  6. Trumbull, Connecticut
  7. Aventura, Florida
  8. Tampa, Florida
  9. Atlanta, Georgia
  10. Boise, Idaho
  11. Idaho Falls, Idaho
  12. Springfield, Illinois
  13. Indianapolis, Indiana
  14. New Orleans, Louisiana
  15. Portland, Maine
  16. Cumberland, Maryland
  17. Worcester, Massachusetts
  18. Flowood, Mississippi
  19. Tupelo, Mississippi
  20. Lebanon, New Hampshire
  21. Voorhees, New Jersey
  22. Rocky Mount, North Carolina
  23. Bethlehem, Pennsylvania
  24. Willow Grove, Pennsylvania
  25. Wyomissing, Pennsylvania
  26. Hixson, Tennessee
  27. Knoxville, Tennessee
  28. Nashville, Tennessee
  29. Dallas, Texas
  30. Dallas, Texas
  31. Fort Worth, Texas
  32. Houston, Texas
  33. Lubbock, Texas
  34. Vancouver, Washington
  35. Vancouver, Washington
  36. Vancouver, Washington
  37. Kogarah, New South Wales
  38. Daw Park, South Australia
  39. Heidelberg, Victoria
  40. Wien,
  41. Wien,
  42. Wien,
  43. Wien,
  44. Genk,
  45. Hasselt,
  46. Kortrijk,
  47. Liège,
  48. Goiania, GO
  49. Curitiba, PR
  50. Porto Alegre, RS
  51. Sao Paulo, SP
  52. Winnipeg, Manitoba
  53. Hamilton, Ontario
  54. Hamilton, Ontario
  55. Ottawa, Ontario
  56. Montreal, Quebec
  57. Pointe Claire, Quebec
  58. Amiens,
  59. Lyon,
  60. Orleans Cedex 1,
  61. Orleans,
  62. Paris,
  63. Paris,
  64. Berlin,
  65. Berlin,
  66. Erlangen,
  67. Frankfurt am Main,
  68. Halle,
  69. Hamburg,
  70. Koeln,
  71. Leipzig,
  72. Rheine,
  73. Wuerzburg,
  74. Croom, Co. Limerick
  75. Dublin,
  76. Firenze,
  77. Jesi,
  78. Busan,
  79. Daegu,
  80. Seoul,
  81. San Juan,
  82. Santiago de Compostela, A Coruña
  83. Merida, Badajoz
  84. Bilbao, Bizkaia
  85. Santander, Cantabria
  86. Baracaldo, Vizcaya
  87. Madrid,
  88. Valencia,
  89. Niao Sung Hsiang, Kaohsiung County
  90. Kweishan, Taoyuan County
  91. Changhua,
  92. Kaohsiung,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Arthritis, RheumatoidSafety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis NCT02092467
  1. Groton, Connecticut
  2. Huntsville, Alabama
  3. Huntsville, Alabama
  4. Tuscaloosa, Alabama
  5. Tucson, Arizona
  6. Tucson, Arizona
  7. Tucson, Arizona
  8. Hot Springs, Arkansas
  9. Jonesboro, Arkansas
  10. Covina, California
  11. Fair Oaks, California
  12. La Jolla, California
  13. Long Beach, California
  14. Northridge, California
  15. Placentia, California
  16. Rancho Mirage, California
  17. Roseville, California
  18. San Diego, California
  19. Santa Monica, California
  20. Torrance, California
  21. Torrance, California
  22. Torrance, California
  23. Tustin, California
  24. Van Nuys, California
  25. Ventura, California
  26. Victorville, California
  27. Whittier, California
  28. Colorado Springs, Colorado
  29. Washington, District of Columbia
  30. Boca Raton, Florida
  31. Brandon, Florida
  32. Clearwater, Florida
  33. Clearwater, Florida
  34. Clearwater, Florida
  35. Daytona Beach, Florida
  36. Jacksonville, Florida
  37. Jacksonville, Florida
  38. Jacksonville, Florida
  39. Jacksonville, Florida
  40. Miami Lakes, Florida
  41. Miami, Florida
  42. Miami, Florida
  43. Ocala, Florida
  44. Ocoee, Florida
  45. Orange Park, Florida
  46. Orlando, Florida
  47. Orlando, Florida
  48. Ormond Beach, Florida
  49. Palm Harbor, Florida
  50. Palm Harbor, Florida
  51. Port Orange, Florida
  52. Port Orange, Florida
  53. Tampa, Florida
  54. Tampa, Florida
  55. Zephyrhills, Florida
  56. Canton, Georgia
  57. Decatur, Georgia
  58. Coeur d'Alene, Idaho
  59. Quincy, Illinois
  60. Springfield, Illinois
  61. Springfield, Illinois
  62. Indianapolis, Indiana
  63. Wichita, Kansas
  64. Monroe, Louisiana
  65. Cumberland, Maryland
  66. Frederick, Maryland
  67. Hagerstown, Maryland
  68. Wheaton, Maryland
  69. Fall River, Massachusetts
  70. Worcester, Massachusetts
  71. Battle Creek, Michigan
  72. Battle Creek, Michigan
  73. Kalamazoo, Michigan
  74. Kalamazoo, Michigan
  75. Lansing, Michigan
  76. Saint Clair Shores, Michigan
  77. Rochester, Minnesota
  78. Kansas City, Missouri
  79. Springfield, Missouri
  80. Kalispell, Montana
  81. Kalispell, Montana
  82. Lincoln, Nebraska
  83. Omaha, Nebraska
  84. Las Vegas, Nevada
  85. Las Vegas, Nevada
  86. Las Vegas, Nevada
  87. Las Vegas, Nevada
  88. Nashua, New Hampshire
  89. Nashua, New Hampshire
  90. Clifton, New Jersey
  91. Brooklyn, New York
  92. Great Neck, New York
  93. Lake Success, New York
  94. Durham, North Carolina
  95. Greenville, North Carolina
  96. Hickory, North Carolina
  97. Hickory, North Carolina
  98. Hickory, North Carolina
  99. Hickory, North Carolina
  100. Statesville, North Carolina
  101. Wilmington, North Carolina
  102. Minot, North Dakota
  103. Cincinnati, Ohio
  104. Dayton, Ohio
  105. Oklahoma City, Oklahoma
  106. Oklahoma City, Oklahoma
  107. Oklahoma City, Oklahoma
  108. Oklahoma City, Oklahoma
  109. Duncansville, Pennsylvania
  110. Philadelphia, Pennsylvania
  111. Pittsburgh, Pennsylvania
  112. Wyomissing, Pennsylvania
  113. Charleston, South Carolina
  114. Charleston, South Carolina
  115. Greenville, South Carolina
  116. Greenville, South Carolina
  117. Orangeburg, South Carolina
  118. Summerville, South Carolina
  119. Jackson, Tennessee
  120. Knoxville, Tennessee
  121. Memphis, Tennessee
  122. Amarillo, Texas
  123. Austin, Texas
  124. Carrollton, Texas
  125. Cypress, Texas
  126. Dallas, Texas
  127. Dallas, Texas
  128. Dallas, Texas
  129. Dallas, Texas
  130. Dallas, Texas
  131. Dallas, Texas
  132. Houston, Texas
  133. Houston, Texas
  134. Houston, Texas
  135. Houston, Texas
  136. Houston, Texas
  137. Lubbock, Texas
  138. Mesquite, Texas
  139. Nassau Bay, Texas
  140. Plano, Texas
  141. Chesapeake, Virginia
  142. Suffolk, Virginia
  143. Glendale, Wisconsin
  144. C.a.b.a., Buenos Aires
  145. San Fernando, Buenos Aires
  146. Buenos Aires, Caba
  147. C.a.b.a., Caba
  148. Rosario, Santa FE
  149. San Miguel de Tucuman, Tucuman
  150. Caba,
  151. Caba,
  152. Cordoba,
  153. San Juan,
  154. Woodville Sth, South Australia
  155. Fitzroy, Victoria
  156. Heidelberg West, Victoria
  157. Victoria Park, Western Australia
  158. Salvador, BA
  159. Vitoria, Espirito Santo
  160. Juiz De Fora, MG
  161. Belo Horizonte, Minas Gerais
  162. Curitiba, PR
  163. Porto Alegre, RIO Grande DO SUL
  164. Rio de Janeiro, RJ
  165. Sao Jose do Rio Preto, SAO Paulo
  166. Campinas, SP
  167. Sao Paulo, SP
  168. Sao Paulo, SP
  169. Rio Grande De Sul,
  170. Sao Paulo,
  171. Sao Paulo,
  172. Sao Paulo,
  173. Sao Paulo,
  174. Pleven,
  175. Plovdiv,
  176. Ruse,
  177. Sofia,
  178. Sofia,
  179. Varna,
  180. Edmonton, Alberta
  181. Victoria, British Columbia
  182. Ottawa, Ontario
  183. Windsor, Ontario
  184. Rimouski, Quebec
  185. Trois-Rivieres, Quebec
  186. Santiago, Metropolitana
  187. Temuco, Region DE LA Araucania
  188. Santiago, Region Metropolitana
  189. Guangzhou, Guangdong
  190. Medellin, Antioquia
  191. Bogota D.C., Cundinamarca
  192. Bogota, Cundinamarca
  193. Chia, Cundinamarca
  194. Bucaramanga, Santander
  195. Ostrava, Czech Republic
  196. Ostrava, Czech Republic
  197. Ostrava, Czech Republic
  198. Praha 11, Czech Republic
  199. Praha, Czech Republic
  200. Brno - Zidenice,
  201. Brno, Cerna Pole,
  202. Brno,
  203. Brno,
  204. Brno,
  205. Brno,
  206. Brno,
  207. Brno,
  208. Brno,
  209. Ostrava,
  210. Praha 2,
  211. Praha 2,
  212. Praha 4,
  213. Praha 4,
  214. Zlin,
  215. Zlin,
  216. Zlin,
  217. Helsinki,
  218. Helsinki,
  219. Helsinki,
  220. Hyvinkaa,
  221. Hyvinkaa,
  222. Chai Wan, HKG
  223. Hong Kong,
  224. Shatin,
  225. Tuen Mun, New Territories,
  226. Ashkelon,
  227. Haifa,
  228. Haifa,
  229. Haifa,
  230. Jerusalem,
  231. Kfar Saba,
  232. Tel Aviv,
  233. Tel-Hashomer,
  234. Zerifin,
  235. Amman,
  236. Lebanon,
  237. Ipoh, Perak
  238. Kuching, Sarawak
  239. Batu Caves, Selangor
  240. Torreon, Coahuila
  241. Mexico, Distrito Federal
  242. Mexico, Distrito Federal
  243. Mexico, Distrito Federal
  244. Guadalajara, Jalisco
  245. Guadalajara, Jalisco
  246. Morelia, Michoacan
  247. Morelia, Michoacan
  248. Culiacan, Sinaloa
  249. Merida, Yucatan
  250. Merida, Yucatan
  251. Merida, Yucatan
  252. Chihuahua,
  253. San Luis Potosi,
  254. San Luis Potosi,
  255. Leeuwarden,
  256. Utrecht,
  257. Auckland,
  258. Auckland,
  259. Hamilton,
  260. Hamilton,
  261. Timaru,
  262. Timaru,
  263. Wellington,
  264. Wellington,
  265. Trujillo, LA Libertad
  266. Pueblo Libre, Lima
  267. Arequipa,
  268. Lima, Lima,
  269. Lima,
  270. Lima,
  271. Lima,
  272. Lima,
  273. Lima,
  274. Lima,
  275. Lima,
  276. Lima,
  277. Nadarzyn, Mazowieckie
  278. Nadarzyn, Mazowieckie
  279. Warszawa, Mazowieckie
  280. Bialystok, Podlaskie
  281. Gdynia, Pomorskie
  282. Gdynia, Pomorskie
  283. Bydgoszcz,
  284. Bydgoszcz,
  285. Elblag,
  286. Gdynia,
  287. Katowice,
  288. Lublin,
  289. Lublin,
  290. Poznan,
  291. Sopot,
  292. Staszow,
  293. Torun,
  294. Torun,
  295. Torun,
  296. Warsaw,
  297. Warszawa,
  298. Wroclaw,
  299. Wroclaw,
  300. Wroclaw,
  301. Ponce,
  302. Ponce,
  303. San Juan,
  304. Saint-Petersburg, Sestroretsk CITY
  305. St.Petersburg, Sestroretsk CITY
  306. Moscow,
  307. Moscow,
  308. Nizhniy Novgorod,
  309. Novosibirsk,
  310. Novosibirsk,
  311. Novosibirsk,
  312. Petrozavodsk,
  313. Smolensk,
  314. St. Petersburg,
  315. Yekaterinburg,
  316. Yekaterinburg,
  317. Yekaterinburg,
  318. Bratislava,
  319. Bratislava,
  320. Dunajska Streda,
  321. Nitra,
  322. Nove Zamky,
  323. Partizanske,
  324. Rimavska Sobota,
  325. Trnava,
  326. Port Elizabeth, Eastern CAPE
  327. Johannesburg, Gauteng
  328. Kempton Park, Gauteng
  329. Pretoria, Gauteng
  330. Pretoria, Gauteng
  331. Wilkoppies, Klerksdorp
  332. Durban, Kwa-zulu Natal
  333. Cape Town, Western CAPE
  334. Cape Town, Western CAPE
  335. Stellenbosch, Western CAPE
  336. Cape Town,
  337. Cape Town,
  338. Merida, Badajoz
  339. Santander, Cantabria
  340. Santiago de Compostela, LA Coruna
  341. Bilbao, Vizcaya
  342. Barcelona,
  343. Barcelona,
  344. Malaga,
  345. Sevilla,
  346. Changhua,
  347. Chia-Yi,
  348. Taichung,
  349. Tainan,
  350. Tainan,
  351. Taipei,
  352. Taoyuan City,
  353. Bangkok,
  354. Bangkok,
  355. Bangkok,
  356. Chiang Mai,
  357. Songkhla,
  358. Aydin,
  359. Aydin,
  360. Diyarbakir,
  361. Gaziantep,
  362. Gaziantep,
  363. Gaziantep,
  364. Izmir,
  365. Izmir,
  366. Manisa,
  367. Manisa,
  368. Samsun,
  369. Poole, Dorset
  370. Poole, Dorset
  371. Goodmayes, Essex
  372. Cannock,
  373. Liverpool,
  374. Liverpool,
  375. Liverpool,
  376. Newcastle Upon Tyne,
  377. Newcastle Upon Tyne,
  378. Newcastle Upon Tyne,
  379. North Shields,
  380. Wolverhampton,
ALL GENDERS
50 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis
Official Title  ICMJE PHASE 3B/4 RANDOMIZED SAFETY ENDPOINT STUDY OF 2 DOSES OF TOFACITINIB IN COMPARISON TO A TUMOR NECROSIS FACTOR (TNF) INHIBITOR IN SUBJECTS WITH RHEUMATOID ARTHRITIS
Brief Summary This post-marketing study is designed to compare the safety of tofacitinib versus TNF inhibitor with respect to major cardiovascular adverse events and malignancies, excluding non-melanoma skin cancers when given to subjects with rheumatoid arthritis. Other safety events, including non-melanoma skin cancers, hepatic events, infections, and efficacy parameters will be collected and evaluated in the study.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Arthritis, Rheumatoid
Intervention  ICMJE
  • Drug: tofacitinib
    Oral tablet, 5 mg BID
  • Drug: tofacitinib
    Oral tablet, 10 mg BID
  • Biological: adalimumab
    Pre-filled syringe, 40 mg subcutaneous injection, every other week
    Other Name: Humira
  • Biological: etanercept
    Pre-filled syringe, 50 mg subcutaneous injection, every week
    Other Name: Enbrel
Study Arms  ICMJE
  • Experimental: Treatment Arm 1
    Intervention: Drug: tofacitinib
  • Experimental: Treatment Arm 2
    Intervention: Drug: tofacitinib
  • Active Comparator: Treatment Arm 3
    TNF inhibitor Arm - adalimumab will be used in US, Canada and Puerto Rico; etanercept will be used in all other countries.
    Interventions:
    • Biological: adalimumab
    • Biological: etanercept
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: June 1, 2020)		4412
Original Estimated Enrollment  ICMJE
 (submitted: March 18, 2014)		4000
Estimated Study Completion Date  ICMJE June 8, 2020
Estimated Primary Completion Date June 8, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Moderate to severe rheumatoid arthritis
  • Taking methotrexate without adequate control of symptoms
  • Have at least one cardiovascular risk factor (eg, current smoker, high blood pressure, high cholesterol levels, diabetes mellitus, history of heart attack, family history of coronary heart disease, extra-articular RA disease)

Exclusion Criteria:

  • Current or recent infection
  • Clinically significant laboratory abnormalities
  • Pregnancy
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 50 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Argentina,   Australia,   Brazil,   Bulgaria,   Canada,   Chile,   China,   Colombia,   Czechia,   Finland,   Hong Kong,   Israel,   Jordan,   Lebanon,   Malaysia,   Mexico,   Netherlands,   New Zealand,   Peru,   Poland,   Puerto Rico,   Russian Federation,   Slovakia,   South Africa,   Spain,   Taiwan,   Thailand,   Turkey,   United Kingdom,   United States
Removed Location Countries Austria,   Czech Republic,   Sweden
 
Administrative Information
NCT Number  ICMJE NCT02092467
Other Study ID Numbers  ICMJE A3921133
2013-003177-99 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
URL:https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d…
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date June 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP